Salmaan kanji

ICU pharmacist, Pharmacoepidemiologist, Oiler fan

[PharmD uOttawa @uOttawaPharmD]

It is with great pleasure that we announce the appointment of Dr. Christine Landry as the Program Director of @uottawa brand-new PharmD program!
We wish her all the best in her new role !
Read the article here: https://t.co/vDm3W160FT
@ClandryPharmD
@DanielFigeys
@uOttawaMed

[Debanjali @DebanjaliP]

Combination CFTR modulators have revolutionized #cysticfibrosis care, but there remain concerns of drug-drug interactions. Out now in @JournalofCF our review examining these interactions with a focus on Trikafta/Kaftrio 👇👇 https://t.co/HL0qZinCrA

[Carole Lunny @carole_lunny]

The four horsemen of #Grant #writing

[Carole Lunny @carole_lunny]

Please share - Our WISEST survey has reached 500 respondents!

The survey asks how if and how you choose amongst competing #systematicreview s on the same topic. Any field of research is applicable!

Link to the survey is here:
https://t.co/8nPpdhAKlN

Art by @savagechickens

[Salmaan kanji @salkanji]

Too many systematic reviews on the same topic? How do you choose? Our team led by @carole_lunny is working on developing a tool using AI to help YOU choose the one worth reading but we need to hear from you! Please take our 10 minute survey. https://t.co/4guzmJt4Ea

[Carole Lunny @carole_lunny]

@carole_lunny & WISEST team invite decision makers, researchers, healthcare workers, and learners to take part in our survey about the development of a new #AI tool to choose 1 or more #systematicreview when there are many on the same topic.

Survey link https://t.co/pxsEnYmyzi

[Critical Care Reviews @CritCareReviews]

Vitamin C.
A great case of waiting for evidence before exposing patients to interventions of unclear benefit / harm
#LOVITtrial
#CCR22

[Carole Lunny @carole_lunny]

Interested in methods when conducting an "overview of reviews"? Look no further than our paper about managing primary study overlap across systematic reviews ⬇️

[Salmaan kanji @salkanji]

ICI therapy has revolutionized cancer therapy but you must know the risks. Congrats Sydney Morin, ⁦@DebanjaliP⁩ ⁦@PierreThabet⁩ ⁦@kyla_agtarap⁩. Check out our newest overview of systematic reviews. https://t.co/KXCWouzNSN

[Salmaan kanji @salkanji]

ICI therapy has improved the outlook of so many cancers but you have to understand the risks! Lots of adverse events to be aware of. Greater awareness=earlier recognition=better outcomes. @DebanjaliP @PierreThabet

[Debanjali @DebanjaliP]

‼️ Our findings show that, among all of the AEs reported, the most common all-grade AEs are fatigue (18.3%), diarrhea (15.3%), and rash (14.4%).

[Debanjali @DebanjaliP]

🆕 overview of systemic reviews describing incidence proportion and severity of adverse effects associated with immune checkpoint inhibitors. Early recognition of these AEs = better patient outcomes ⬇️ https://t.co/HKRAcKxIs4

[Salmaan kanji @salkanji]

ApARTogether Virtual Showcase https://t.co/ZKQ2HoKGGz

[Michael E Brogan @MEBroganMD]

Great talk on pharmacologic confounders to BD/DNC at #NCS2021. Be conservative.

[Alex Reynolds @AlexReynoldsMD]

Another amazing PharmD talk at #NCS2021 @neurocritical. This time @salkanji speaks to the classic question: “have I waited long enough off sedatives to declare brain death?”

[Eljim @ETNCCRX]

@salkanji discusses pharmacologic confounders in #braindeath @neurocritical:
👉🏽no need to wait for complete elimination, just therapeutic range or less
👉🏽T1/2 altered in ICU
👉🏽prolonged infusions affect Vd, Cl
👉🏽be conservative with estimates

#NCS2021
#NCSPharmacy

[Alexandre Tran @WhatsUp_Doc123]

Our latest SR-MA, published in @AnnalsofSurgery, suggests that among adult trauma patients, LMWH is superior to UFH for DVT and VTE prevention and may additionally reduce pulmonary embolism and mortality.

[The Ottawa Hospital @OttawaHospital]

We’re taking a page from the book of @ottawahealth and using the trusty Twitter thread to share an update on the current COVID-19 situation in our hospital, and hospitals throughout the community.

Please take a minute to read this... [1/9]

[David Juurlink @DavidJuurlink]

Per CDC, COVID vaccines looking impressively safe.

Through Dec 22, after nearly 1 million doses, only 307 ED visits, almost all of them for minor symptoms.

#1: dizziness

[Salmaan kanji @salkanji]

Cross-Country Conversations - Webinar #5: Intensive Care https://t.co/B7WaFCu3j4 via @YouTube. #COVID19Ontario #COVID19 #covid19Canada

[Salmaan kanji @salkanji]

@LAwdishu @hswapnil @caioqualunque @BAMPharmD @erin_barreto Absolutely. Treatment failure rates with Vanco for MRSA infections are 35% at TOH according to our latest study. Associated with under dosing. Coming soon via @ry3a4n